Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPX-Survivac + Cyclophosphamide in Recurrent DLBCL
NCT02323230Phase 2Terminated
- Sponsor
- ImmunoVaccine Technologies Inc.
- Start
- Jan 2015
- Primary completion
- Jun 2017
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maveropepimut-S in diffuse large B-cell lymphoma (DLBCL), sponsored by ImmunoVaccine Technologies Inc. Primary endpoint: Objective Response Rate at 6 months. Started Jan 2015; status: terminated.
02
Drugs
maveropepimut-S
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02323230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02323230.